Replies to post #649335 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Here is the figure I took from Antonio's dissertation. See the purple line? CSF1R-I made big difference.

Also would you agree that the biomarker analysis as shown in the Nature preprint was repeated on hundreds of GBM patients in both clinical trials and the UK Specials Program as well as the patients from compassionate use? Both NWBO and Merck should know very well about immno-suppressive characteristics resulted from macrophage. Here is the interesting thing. The FDA approved CSF1R-I brought no revenue to Daiichi so far.

https://www.daiichisankyo.com/files/investors/library/quarterly_result/2023/FY2023_Q2_Financial_Results_Presentation_E_v2.pdf

[AngeloFoca]

Exactly what I was going to ask... thanxs... for beating me to it.




.